US · MPLT · BIOTECHNOLOGY
MapLight Therapeutics, Inc. (MPLT) intrinsic value and stock valuation
$5.94as of 2026-11-21 · Mkt cap 516.45M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
MapLight Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values MPLT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MPLT’s statements →
MapLight Therapeutics, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2022–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating income | -$-169.08M | -$-82.95M | -$-57.28M | -$-31.25M |
| Net income | -$-161.15M | -$-77.58M | -$-55.71M | -$-30.02M |
| EPSd | -$-3.66M | -$-1.87M | -$-1.34M | -$-724.6K |
| Operating cash flow | -$-138.14M | -$-78.81M | -$-52.01M | -$-26.58M |
| Capital expenditure | -$-470K | -$-770K | -$-460K | -$-750K |
| Free cash flow | -$-138.61M | -$-79.58M | -$-52.47M | -$-27.32M |
| Total assets | $479.5M | $136.9M | $91.4M | $39.4M |
| Total debt | $5.8M | $6.58M | $5.92M | $6.27M |
| Net debt | -$-40.93M | -$-31.67M | -$-73.84M | -$-21.39M |
| Total equity | $458.4M | $115.2M | $71.3M | $20.9M |
| Cash and short-term investments | $305.1M | $108.8M | $79.8M | $27.7M |
Income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $580K | $700K | $560K | $570K |
| Gross profit | -$-580K | -$-700K | -$-560K | -$-570K |
| Research and development expenses | $137.8M | $67.8M | $49.1M | $26.6M |
| Selling, general and administrative expenses | $30.7M | $14.4M | $7.61M | $4.1M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $168.5M | $82.3M | $56.7M | $30.7M |
| Cost and expenses | $169.1M | $83M | $57.3M | $31.3M |
| Interest income | $5.52M | $4.5M | $1.1M | $430K |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $580K | $700K | $560K | $570K |
| Ebitda | -$-160.57M | -$-76.88M | -$-55.15M | -$-29.44M |
| Operating income | -$-169.08M | -$-82.95M | -$-57.28M | -$-31.25M |
| Total other income/expenses, net | $7.93M | $5.37M | $1.57M | $1.23M |
| Income before tax | -$-161.15M | -$-77.58M | -$-55.71M | -$-30.02M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-161.15M | -$-77.58M | -$-55.71M | -$-30.02M |
| Weighted average shares outstanding | $44M | $41.4M | $41.4M | $41.4M |
| Weighted average diluted shares outstanding | $44M | $41.4M | $41.4M | $41.4M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Cash and short-term investments | $305.1M | $108.8M | $79.8M | $27.7M |
| Net receivables | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $324.7M | $114.6M | $83.6M | $32M |
| Property, plant and equipment, net | $6.58M | $7.56M | $6.58M | $7.12M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $148.2M | $11.6M | $1.22M | $230K |
| Total non-current assets | $154.8M | $22.3M | $7.8M | $7.36M |
| Total assets | $479.5M | $136.9M | $91.4M | $39.4M |
| Accounts payable | $0.00 | $1.91M | $3.25M | $3.6M |
| Short-term debt | $890K | $780K | $490K | $350K |
| Deferred revenue | $0.00 | $3.24M | $4.2M | $5.86M |
| Total current liabilities | $16.2M | $15.9M | $14.7M | $12.6M |
| Long-term debt | $4.91M | $5.8M | $5.43M | $5.92M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $4.91M | $5.8M | $5.43M | $5.92M |
| Capital lease obligations | $4.91M | $5.8M | $5.43M | $5.92M |
| Total liabilities | $21.1M | $21.7M | $20.1M | $18.5M |
| Common stock | $10K | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-360.52M | -$-199.37M | -$-121.79M | -$-66.08M |
| Accumulated other comprehensive income (loss) | -$-230K | $160K | $0.00 | $0.00 |
| Total equity | $458.4M | $115.2M | $71.3M | $20.9M |
| Total investments | $406.6M | $82.1M | $1.22M | $230K |
| Total debt | $5.8M | $6.58M | $5.92M | $6.27M |
| Net debt | -$-40.93M | -$-31.67M | -$-73.84M | -$-21.39M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Net income | -$-161.15M | -$-77.58M | -$-55.71M | -$-30.02M |
| Depreciation and amortization | $580K | $700K | $560K | $570K |
| Stock-based compensation | $0.00 | $0.00 | $0.00 | $0.00 |
| Change in working capital | -$-12.84M | -$-3.06M | $2.04M | $1.72M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash provided by operating activities | -$-138.14M | -$-78.81M | -$-52.01M | -$-26.58M |
| Investments in property, plant and equipment | -$-470K | -$-770K | -$-460K | -$-750K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-323.21M | -$-80.79M | -$-460K | -$-750K |
| Common stock issued | $474.8M | $120.3M | $104.6M | $33.2M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $469.8M | $118.1M | $104.6M | $33.2M |
| Net change in cash | $8.48M | -$-41.52M | $52.1M | $27.7M |
| Cash at end of period | $46.7M | $38.3M | $79.8M | $27.7M |
| Operating cash flow | -$-138.14M | -$-78.81M | -$-52.01M | -$-26.58M |
| Capital expenditure | -$-470K | -$-770K | -$-460K | -$-750K |
| Free cash flow | -$-138.61M | -$-79.58M | -$-52.47M | -$-27.32M |
Line items
Line items
Line items
About MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
- CEO
- Christopher A. Kroeger
- Employees
- 133
- Beta
- 2.65
Explore
Frequently asked questions
What is the intrinsic value of MapLight Therapeutics, Inc. (MPLT)?
InvestorsCraft does not currently publish an intrinsic value for MPLT. How the IC value is calculated.
Is MPLT undervalued?
InvestorsCraft does not publish an undervaluation signal for MPLT at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.